Inactive Instrument

Highlights Veru Inc Nasdaq

Equities

US3144621022

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Apr. 01	CI
Veru Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for its Phase 2b Clinical Study	Feb. 06	CI
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with Glp-1 Drugs for Weight Loss	Jan. 08	CI
Veru Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 08	CI
Veru Inc. Reports Muscle Data from 5 Clinical Studies of Enobosarm	23-10-04	CI
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication	23-09-26	CI
Veru Inc. Announces Clinical Data from Its Discontinued Phase 3 ARTEST Clinical Trial of Enobosarm Monotherapy	23-09-11	CI
Earnings Flash (VERU) VERU Posts Q3 Revenue $3.3M	23-08-10	MT
Veru Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-10	CI
Earnings Flash (VERU) VERU Reports Q2 Revenue $6.6M	23-05-11	MT
Veru Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-11	CI
Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS	23-05-04	CI
Veru Sells Entadfi Business for $20 Million Plus Up to $80 Million From Sales Milestones; Shares Up Pre-Bell	23-04-20	MT
Veru Sets Accord With Afaxys to Offer FC2 Female Condom in US Public Health Centers	23-04-19	MT
Veru Says Preclinical Data Show Sabizabulin Inhibits Poxviruses; Shares Rise	23-04-11	MT
Veru Says Influenza Drug Candidate Showed 'Robust' Anti-Inflammatory Activity in Animal Study	23-04-04	MT
Veru Shares Hit 52-Week Low After FDA Denies Emergency Use For Covid-19 Treatment	23-03-03	DJ
US FDA Denies Emergency Use Authorization for Veru's COVID-19 Drug Candidate Sabizabulin	23-03-03	MT
Veru Says FDA Denied Emergency Use Authorization for COVID-19 Drug Candidate Sabizabulin; Shares Plunge Pre-Bell	23-03-03	MT
Veru Inc. Provides FDA Update on Request for Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for ARDS	23-03-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Veru Inc Nasdaq

Equities

US3144621022

Highlights

Filters